Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2/3 1

Status

Recruiting 4Active not recruiting 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 257Neoplasms 225Carcinoma, Non-Small-Cell Lung 206Colorectal Neoplasms 148Prostatic Neoplasms 142Lung Neoplasms 116Neoplasm Metastasis 106Ovarian Neoplasms 103Multiple Myeloma 98Pancreatic Neoplasms 89Leukemia, Myeloid, Acute 79Squamous Cell Carcinoma of Head and Neck 75Endometrial Neoplasms 65Melanoma 64Stomach Neoplasms 60Recurrence 59Glioblastoma 57Brain Neoplasms 56Urinary Bladder Neoplasms 51Carcinoma, Hepatocellular 51Triple Negative Breast Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Lymphoma 48Head and Neck Neoplasms 47Carcinoma, Renal Cell 46Hematologic Neoplasms 44Esophageal Neoplasms 43Colonic Neoplasms 43Uterine Cervical Neoplasms 42Glioma 42

Interventions

Trastuzumab 2tucatinib 1pertuzumab 1Neoadjuvant Therapy 1Genetic Testing 1Docetaxel 1Capecitabine 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Breast Cancer × 30 days × Clear all
NCT04638725 2026-06-04

SIGHER

Centre Paul Strauss

Recruiting
9,000 enrolled
Breast

HER2-positive Breast Cancer

NCT07518173 2026-06-04

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
596 enrolled
Breast

HER2-positive Breast Cancer

NCT07616440 2026-06-04

Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase NA Recruiting
20 enrolled
Breast

HER2-positive Breast Cancer

NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting
650 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡